USANA Health Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Equity-Based Compensation (Tables)

3 Months Ended

Apr. 04, 2015



2015		$ 5,664
2016		6,771
2017		4,484
2018		1,561
2019+		510
		$ 18,990

The cost above is expected to be recognized over a weighted-average period of 1.9 years.



	Three Months Ended

	March 29,	April 4,
	2014	2015

Expected volatility (1)	39.9%	40.4%
Risk-free interest rate (2)	1.2%	1.1%
Expected life (3)	3.54 yrs.	3.30 yrs.
Expected dividend yield (4)	0.0%	0.0%
Weighted-average exercise price (5)	$ 57.62	$ 102.10

(1) The Company utilizes historical volatility of the trading price of its common stock.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.
(3) Depending upon the terms of the award, one of two methods will be used to calculate expected life:
(i) a weighted-average that includes historical settlement data of the Company’s equity awards and a
hypothetical holding period, or (ii) the simplified method.
(4) The Company historically has not paid dividends.
(5) Exercise price is the closing price of the Company's common stock on the date of grant.


	Shares	Weighted-average exercise price	Weighted-average remaining contractual term	Aggregate intrinsic value*
Outstanding at January 3, 2015	1,555	$ 49.20	2.9	$ 82,564
Granted	110	102.10
Exercised	(55)	41.60
Forfeited	(19)	43.83
Expired	-	-

Outstanding at April 4, 2015	1,591	$ 53.18	2.7	$ 97,095

Exercisable at April 4, 2015	66	$ 39.25	2.3	$ 4,954